# Evaluation of an artificial intelligence tool to automate radiotherapy treatment

Submission date	Recruitment status	[X] Prospectively registered
30/06/2022	Recruiting	☐ Protocol
Registration date	Overall study status	Statistical analysis plan
22/09/2022	Ongoing	Results
<b>Last Edited</b> 17/07/2025	Condition category Cancer	Individual participant data
		[X] Record updated in last year

#### Plain English summary of protocol

Background and study aims

The aim of this study is to look at whether an Artificial Intelligence (AI) based computer program can automate two components of the radiotherapy treatment pathway to a sufficient quality standard to enable its routine clinical use. The two components include the delineation (outlining) of anatomical areas that are at risk of tumour spread and at risk of radiation damage, and the definition of the position, size and shape of the radiation beams.

AI-based computer programs have been developed to perform tasks that would normally require direct human involvement by oncologists and medical physicists. Proposed advantages include improved treatment accuracy, as well as a reduction in the time (from weeks to minutes) and human resources needed to deliver radiotherapy, which this study will test.

#### Who can participate?

Patients aged 18 years and over with a new diagnosis of head and neck cancers, cervical cancer or prostate cancer that will be treated with radiotherapy.

#### What does the study involve?

The researchers will use the images from radiotherapy planning CT scan for the study. Following consent for the study, no further information is required from patients.

#### What are the possible benefits and risks of participating?

There are no expected risks as participants will be treated according to the standard treatment plan with no additional tests or treatment required. There is no immediate benefit for participants in this study as they will be treated according to the current standard. It is hoped that the information from this study will help to improve treatment for future patients with cancer.

Where is the study run from? MRC CTU at UCL (UK)

When is the study starting and how long is it expected to run for? June 2021 to September 2026

Who is funding the study?

- 1. National Institutes of Health (NIH) (USA)
- 2. Rising Tide Foundation for Clinical Cancer Research (Switzerland)

Who is the main contact?

Dr Ajay Aggarwal, mrcctu.archery@ucl.ac.uk

#### Study website

https://archery.mrcctu.ucl.ac.uk/

# **Contact information**

#### Type(s)

Principal Investigator

#### Contact name

Dr Ajay Aggarwal

#### Contact details

MRC CTU at UCL 90 High Holborn London United Kingdom WC1V 6LJ +44 (0)20 7670 4700 mrcctu.archery@ucl.ac.uk

### Additional identifiers

#### EudraCT/CTIS number

Nil known

**IRAS** number

#### ClinicalTrials.gov number

NCT05653063

# Secondary identifying numbers

AI01

# Study information

#### Scientific Title

ARCHERY - A prospective observational study of artificial intelligence based radiotherapy treatment planning for cervical, head and neck, and prostate cancer

#### Acronym

**ARCHERY** 

#### Study objectives

Current study hypothesis as of 22/05/2024:

Al can automate target volume contouring and produce radiotherapy plans that are able to meet international standards for treatment quality

#### Previous study hypothesis:

Al can automate target volume delineation and produce radiotherapy plans that are able to meet international standards for treatment quality

#### Ethics approval required

Old ethics approval format

#### Ethics approval(s)

Approved 25/04/2023, University College London Research Ethics Committee (Research Ethics Team, Office of the Vice-Provost (Research), University College London, 2 Taviton Street, London, WC1H 0BT, United Kingdom; N/A; ethics@ucl.ac.uk), ref: 24627.001

#### Study design

Prospective observational cohort study

#### Primary study design

Observational

#### Secondary study design

Cohort study

#### Study setting(s)

Hospital

#### Study type(s)

Treatment

#### Participant information sheet

Not available in web format, please use contact details to request a participant information sheet

#### Health condition(s) or problem(s) studied

Cervical, head and neck, and prostate cancer

#### **Interventions**

A web-based artificial intelligence (AI) auto-planning tool

The CT scan taken at the time of treatment planning is uploaded to a web server called the Radiotherapy planning assistant which automates the contouring of target organs and areas of high-risk disease as well as defining the size, shape and number of radiotherapy beams to treat the cancer. The final plan is downloaded to the local treatment planning system where the doses are recalculated and clinical peer review is undertaken before the plan can be used clinically.

In this study patients will not be treated with the AI tool but the manual plan created by the local teams. As the participants will not be receiving the intervention, there will be no follow-up for participants.

#### Intervention Type

Other

#### Primary outcome measure

Current primary outcome measure as of 17/07/2025:

Overall acceptability of the automated treatment plan. This is a composite outcome including both the assessment of the delineated clinical target volumes (CTVs) and organs-at-risk (OARs) with reference to internationally accepted contouring guidelines and the adherence to predefined dosimetric constraints for each tumour type. Timepoint: clinical peer review.

Previous primary outcome measure:

Overall acceptability of the automated treatment plan. This is a composite outcome including both the assessment of the delineated clinical target volumes (CTVs) and organs-at-risk (OARs) using a pre-defined scale and the adherence to acceptable dosimetric constraints for each tumour type. Timepoint: clinical peer review.

#### Secondary outcome measures

- 1. Time and resource savings measured during manual and automated processes:
- 1.1. Date/time CT planning scan performed
- 1.2. Date/time of delineation started/completed (grade and number of staff members)
- 1.3. Date/time of radiotherapy treatment planning completed (grade and number of staff members involved)
- 1.4. Date/time CT (with gross tumor volume [GTV] contoured manually) sent for autcontouring and planning
- 1.5. Date/time autocontouring and planning completed
- 2. Cost-effectiveness measured using time-driven activity-based costing tool based on timing and resource use inputs

Timepoint: clinical peer review

#### Overall study start date

01/06/2021

#### Completion date

01/09/2026

# **Eligibility**

#### Key inclusion criteria

Current inclusion criteria as of 17/07/2025:

- 1. Patients with:
- 1.1. Histologically confirmed head and neck cancers of the oropharynx, larynx, hypopharynx, and nasopharynx (American Joint Committee on Cancer [AJCC] Stage I-IVB) that have given consent for radical radiotherapy (with or without concurrent chemotherapy). Patients can be included if they have had induction chemotherapy prior to radiotherapy OR

1.2. Histologically confirmed primary cervical cancer (International Federation of Gynaecology and Obstetrics [FIGO]/AJCC Stage IB-IIIC1) that have given consent for radical radiotherapy (with or without concurrent chemotherapy). Patients can be included if they have had induction chemotherapy prior to radiotherapy.

OR

- 1.3. Histologically confirmed primary prostate cancer (AJCC Stage I-IIIC) that have given consent for radical radiotherapy. Patients can be included if they have had prior chemotherapy or are taking a hormonal therapy for their prostate cancer.
- 2. Provide signed informed consent to participate in the study
- 3. Aged ≥18 years

Previous inclusion criteria as of 22/05/2024:

- 1. Patients with:
- 1.1. Histologically confirmed head and neck cancers of the oropharynx, larynx, hypopharynx, and nasopharynx (American Joint Committee on Cancer [AJCC] Stage I-IVB) that have given consent for radical radiotherapy. Patients can be included if they have had induction chemotherapy prior to radiotherapy

OR

- 1.2. Histologically confirmed primary cervical cancer (International Federation of Gynaecology and Obstetrics [FIGO]/AJCC Stage IB-IIIC1) that have given consent for radical radiotherapy OR
- 1.3. Histologically confirmed primary prostate cancer (AJCC Stage I-IIIC) that have given consent for radical radiotherapy
- 2. Provide signed informed consent to participate in the study
- 3. Aged ≥18 years

Previous inclusion criteria:

- 1. Consecutive patients at each participating centre with histologically confirmed head and neck cancers of the oropharynx, larynx, hypopharynx and nasopharynx (Stage I-III) that have given consent for primary curative radiotherapy
- 2. Consecutive histologically confirmed primary cervical cancer patients (Stage IB-IIIB including pelvic node positive) that have given consent for radical radiotherapy
- 3. Patients aged over 18 years
- 4. Written informed consent to participate in the study

#### Participant type(s)

Patient

#### Age group

Adult

#### Lower age limit

18 Years

Sex

#### Both

#### Target number of participants

330 for cervical cancer; 330 for head and neck cancer; 330 for prostate cancer

#### Key exclusion criteria

Current exclusion criteria as of 17/07/2025:

- 1. Patients requiring radiotherapy after curative surgery or surgery that is intended to remove as much of the tumour as possible
- 2. Patients receiving a palliative dose of radiotherapy
- 3. Patients that have any metal implants within the treatment field e.g. hip prostheses. Dental implants are acceptable.

Previous exclusion criteria as of 22/05/2024:

- 1. Patients requiring radiotherapy after curative surgery or surgery that is intended to remove as much of the tumour as possible
- 2. Patients receiving palliative radiotherapy

Previous exclusion criteria:

1. Patients requiring radiotherapy after curative or de-bulking surgery

#### Date of first enrolment

27/12/2023

#### Date of final enrolment

01/12/2025

#### Locations

#### Countries of recruitment

India

Jordan

Malaysia

South Africa

Study participating centre
University of Malaya Medical Center
Lembah Pantai
Kuala Lumpur

Malaysia 59100

#### Study participating centre King Hussein Cancer Center

Queen Rania St 202 Amman Jordan 11733

# Study participating centre Tygerberg Academic Hospital, Stellenbosch University

6 Jan Celliers Rd Stellenbosch Central Stellenbosch South Africa 7600

#### Study participating centre Groote Schuur Hospital, University of Cape Town

Main Rd Observatory Cape Town South Africa 7935

#### Study participating centre Tata Memorial Hospital

Parel East Parel Mumbai India 400012

#### Study participating centre Tata Medical Center

14, MAR(E-W)
DH Block (Newtown)
Action Area I
Newtown
Kolkata

# Sponsor information

#### Organisation

University College London

#### Sponsor details

MRC CTU at UCL
90 High Holborn
London
England
United Kingdom
WC1V 6LJ
+44 (0)20 7670 4700
mrcctu.ctuenquiries@ucl.ac.uk

#### Sponsor type

University/education

#### Website

https://www.mrcctu.ucl.ac.uk/

#### **ROR**

https://ror.org/02jx3x895

# Funder(s)

#### Funder type

Government

#### **Funder Name**

National Institutes of Health

#### Alternative Name(s)

Institutos Nacionales de la Salud, US National Institutes of Health, NIH

#### **Funding Body Type**

Government organisation

#### **Funding Body Subtype**

National government

#### Location

United States of America

#### **Funder Name**

Rising Tide Foundation for Clinical Cancer Research

#### Alternative Name(s)

**RTFCCR** 

#### **Funding Body Type**

Private sector organisation

#### **Funding Body Subtype**

Trusts, charities, foundations (both public and private)

#### Location

Switzerland

#### **Results and Publications**

#### Publication and dissemination plan

Planned publications in high-impact peer-reviewed journals

#### Intention to publish date

01/09/2026

#### Individual participant data (IPD) sharing plan

The datasets generated during and/or analysed during the current study are/will be available upon request from Dr Ajay Aggarwal (mrcctu.archery@ucl.ac.uk).

Data will be shared according to the MRC CTU and UCL's controlled access approach, based on the following principles:

- 1. No data should be released that would compromise an ongoing trial or study.
- 2. There must be a strong scientific or other legitimate rationale for the data to be used for the requested purpose.
- 3. Investigators who have invested time and effort into developing a trial or study should have a period of exclusivity in which to pursue their aims with the data, before key trial data are made available to other researchers.
- 4. The resources required to process requests should not be under-estimated, particularly successful requests which lead to preparing data for release. Therefore adequate resources must be available in order to comply in a timely manner or at all, and the scientific aims of the study must justify the use of such resources.
- 5. Data exchange complies with Information Governance and Data Security Policies in all of the relevant countries.

Applications for data can be made at any time and will be considered on a case-by-case basis. Researchers wishing to access ARCHERY data should contact the Trial Management Group in the

first instance. Following approval of a request, a formal agreement will be drawn up between the relevant parties prior to the release of any data, and measures will be put in place to ensure that ethical and regulatory requirements relating to data confidentiality are upheld.

#### IPD sharing plan summary

Available on request